Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
GE
Generate Biomedicines, Inc. Common Stock
GENB
Mkt Cap
$1.55B
Volume
938.84K
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
GE
GENB
GE
Generate Biomedicines, Inc. Common Stock
GENB
News
·
Pharmaceutical Market Research: Global Industry to Reach USD 3.22 Trillion by 2035 as Biologics, AI-Driven Drug Discovery, and Manufacturing Investments Reshape Competition
Mkt Cap
$1.68B
Volume
938.84K
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Insider
Filings
Pharmaceutical Market Research: Global Industry to Reach USD 3.22 Trillion by 2035 as Biologics, AI-Driven Drug Discovery, and Manufacturing Investments Reshape Competition
The global pharmaceutical market is projected to grow from USD 1.88 trillion in 2026 to USD 3.22 trillion by 2035 at a 6.15% CAGR. India's pharmaceutical market recorded 17.1% year-over-year growth in September 2026. Key growth drivers include biologics, AI-driven drug discovery, specialty medicines, and manufacturing investments. Asia Pacific is expected to grow faster than the global average at 7.02% CAGR, while North America maintains 36% market share.
GlobeNewswire Inc. · Oct 16, 2026
Cathie Wood Likes That New Stock Smell: 3 IPO Stocks She Bought on Monday
Cathie Wood's Ark Invest expanded positions in three recently-IPO'd stocks on Monday: Space Exploration Technologies (SpaceX), Generate Biomedicines, and Bullish. SpaceX, trading 19% above its IPO price, joins the Nasdaq-100 on Tuesday which should drive passive buying. Generate Biomedicines, a clinical-stage biotech company with AI-driven drug discovery, is trading above its February IPO price. Bullish, a crypto exchange and media company, has plummeted 72% since going public due to crypto market weakness.
The Motley Fool · Jul 7, 2026
Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion Market
Nvidia's venture capital arm has invested $13 million in Generate Biomedicines, a biotech company developing an AI platform for virtual drug testing. The platform addresses major pharmaceutical industry challenges by reducing development time and costs, with AI-discovered drugs showing twice the success rate in phase 1 trials. This investment signals Nvidia's confidence in the company's potential to transform the $1.8 trillion pharmaceutical market.
The Motley Fool · Jun 27, 2026
A Deep Dive Into Nvidia’s Latest Portfolio Moves
Nvidia's Q1 2026 13F filing reveals strategic investments in semiconductor and cloud companies, though some announced investments don't appear due to different security structures. The company significantly increased its CoreWeave holdings to $3.657 billion (95% increase in shares), made equal $2 billion investments in both CoreWeave and Nebius, and invested in Coherent for optical networking. Nvidia also made a small $10.4 million biotech investment in Generate Biomedicines.
Investing.com · May 20, 2026
Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight
The severe asthma drug development pipeline shows strong momentum with 30+ pharmaceutical companies actively developing 35+ pipeline therapies across various clinical stages. Key players including AstraZeneca, Generate Biomedicines, GSK, and others are advancing promising candidates targeting thymic stromal lymphopoietin inhibitors and interleukin pathways. Recent approvals and positive trial results, including GSK's Exdensur and Upstream Bio's verekitug, demonstrate progress in addressing this unmet medical need.
GlobeNewswire Inc. · Apr 7, 2026
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
GE
GENB
Generate Biomedicines, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
GENB
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any GENB yet.
Related Tickers
Earnings